Lexicon Pharma Appoints New CMO, Adds Director
Ticker: LXRX · Form: 8-K · Filed: Jan 2, 2025
Sentiment: neutral
Topics: executive-appointment, board-election, personnel-change
Related Tickers: LXRX
TL;DR
Lexicon Pharma beefs up leadership with a new CMO and board member.
AI Summary
Lexicon Pharmaceuticals, Inc. announced on January 2, 2025, the appointment of Dr. Tamara Joseph as Chief Medical Officer and the election of Ms. Michelle L. Griffin to its Board of Directors. The company also reported on compensatory arrangements for its named executive officers.
Why It Matters
These executive and board changes can signal shifts in company strategy, leadership focus, and potentially impact future clinical development and governance.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Lexicon Pharmaceuticals, Inc. (company) — Registrant
- Dr. Tamara Joseph (person) — Appointed Chief Medical Officer
- Ms. Michelle L. Griffin (person) — Elected to Board of Directors
- January 2, 2025 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Tamara Joseph has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors?
Ms. Michelle L. Griffin has been elected to the Board of Directors.
What is the reporting date for this Form 8-K?
The date of the earliest event reported is January 2, 2025.
What other information is disclosed regarding executive officers?
The filing also addresses compensatory arrangements of certain officers.
In which state is Lexicon Pharmaceuticals, Inc. incorporated?
Lexicon Pharmaceuticals, Inc. is incorporated in Delaware.
Filing Stats: 958 words · 4 min read · ~3 pages · Grade level 10.3 · Accepted 2025-01-02 16:04:14
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 LXRX The Nasdaq Global Select Market
- $450,000 — eceive an initial annual base salary of $450,000 and will be eligible to receive an annu
Filing Documents
- lxrx-20250102.htm (8-K) — 28KB
- exh101-coianteofferletter0.htm (EX-10.1) — 15KB
- 0001062822-25-000003.txt ( ) — 169KB
- lxrx-20250102.xsd (EX-101.SCH) — 2KB
- lxrx-20250102_lab.xml (EX-101.LAB) — 21KB
- lxrx-20250102_pre.xml (EX-101.PRE) — 12KB
- lxrx-20250102_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 — Offer Letter, dated December 18 , 2024, with Scott M. Coi ante EX-104 — Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Lexicon Pharmaceuticals, Inc. Date: January 2, 2025 By: /s/ Brian T. Crum Brian T. Crum Senior Vice President and General Counsel